EQL Pharma
54 SEK 0%Be the first to follow this company
EQL Pharma is a pharmaceutical company. Currently, the focus is on development of niche and specialised pharmaceuticals, including everything from pharma for the treatment of diabetes, enlargement of blood vessels, as well as various infections and allergies. Primarily business is found in the Nordic market. EQL Pharma was founded in 2006 and is based in Lund.
Revenue
-
EBIT %
-
P/E
69.23
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
EQL
Daily low / high price
54 / 54.8
SEK
Market cap
1.57B SEK
Turnover
253.27K SEK
Volume
4.7K
Financial calendar
Interim report
2024-08-08
General meeting
2024-08-19
Interim report
2024-10-24
Interim report
2025-01-31
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Cadila Pharmaceuticals Ltd | 30.0 % | 30.0 % |
Christer Fåhraeus | 24.2 % | 24.2 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Kallelse till årsstämma i EQL Pharma AB
Invitation to presentation in connection with EQL Pharma's interim report, first quarter, 2024/25
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools